Table 3: Lesion efficacy results.
|
Assessment |
Adjusted mean (SE) |
2-sided P-valueb |
Treatment difference (SE) |
2-sided P-value (90% CI) |
|
After first use (day 2)a |
|
|
||
|
Number of lesionsc |
|
|
||
|
No adhesive (n = 9) |
4.10 (0.716) |
[< 0.001] |
2.42 (0.970) |
0.036 (0.63, 4.21) |
|
Adhesive (n = 10) |
1.68 (0.658) |
[0.022] |
NA |
NA |
|
Average size of lesionsd mm2 |
|
|
||
|
No adhesive (n = 9) |
21.77 (5.285) |
[0.001] |
16.86 (6.465) |
0.031 (4.88, 28.84) |
|
Adhesive (n = 10) |
4.91 (4.839) |
[0.327] |
NA |
NA |
|
Average of days 2 and 3e |
|
|
||
|
Number of lesionsc |
|
|
||
|
No adhesive (n = 18) |
4.25 (0.536) |
[< 0.001] |
2.67 (0.744) |
0.007 (1.29, 4.05) |
|
Adhesive (n = 19) |
1.58 (0.498) |
[0.006] |
NA |
NA |
|
Average size of lesionsd mm2 |
|
|
||
|
No adhesive (n = 18) |
26.00 (7.177) |
[0.003] |
21.85 (9.246) |
0.044 (4.75, 38.95) |
|
Adhesive (n = 19) |
4.15 (6.616) |
[0.540] |
NA |
NA |
Abbreviations: NA: not applicable; n: number of observations per treatment for after first use; number of observations per treatment across days 2 and 3 for average of days 2 and 3; a: Analysis of covariance for crossover design included baseline, period, and treatment as fixed effects and participant as a random effect; b: Tests adjusted mean versus zero; c: Overall baseline mean = 1.66; d: Overall baseline mean = 16.19; e: Repeated measures analysis of covariance for crossover design included baseline, day, treatment, and period as fixed effects and participant and participant × period as random effects